Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available

https://doi.org/10.17749/2070-4909.2019.12.2.115-124

Full Text:

Abstract

Since generics and biosimilars have entered the Russian market of medications, there are new trends in the general picture of drug prices and consumption. In the present study, we analyze these trends to enable the prediction of possible savings or redistribution of funds in the area of anticancer drug supply, with a special view on highly expensive medications.

The aim of this study is to identify changes in the market prices and consumption of medications for the treatment of solid tumors.

Materials and methods. We analyzed the dynamics of prices and consumption rates of eight international non-proprietary names (INN) of anticancer drugs, whose generics or biosimilars entered the Russian pharmaceutical market in 2010-2018.

Results. With an overall downward trend in prices, differences between individual drugs become apparent with time of joint circulation in the market. The rates of increase/decrease in the prices of the reference drugs that circulate together with generics/biosimilars for at least 4 years, have changed from -50 to +22%; for the respective generics/biosimilars, the figures ranged from -35 to -69%. After generics/biosimilars have entered the market in the Russian Federations, the consumption of the INNs have been increasing, but again with different paces for different drugs.

Conclusion. With a general downward trend in prices and an increase in consumption of anticancer medications, there are significant differences in this dynamics as far as individual INNs are concerned. Additional studies are needed to identify factors having an impact on the prices and drug consumption of INNs after their generics/biosimilars have become available. For example, the number of original drugs with expired patent protection may be important. Without a good understanding of such factors, it is difficult to predict the size of savings and the possibility of their redistribution within the budget framework.

About the Authors

F. V. Gorkavenko
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

Filipp V. Gorkavenko - Leading Specialist, Department of Methodological Support for Comprehensive Health Technology Assessment, Researcher ID: A-8805-2017.

10-5 Khokhlovskii pereulok, Moscow 109028, Tel.: +7(495)7831905



A. V. Nikitina
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

Anna V. Nikitina - Chief Specialist, Department of Methodological Support for Comprehensive HTA.

10-5 Khokhlovskii pereulok, Moscow 109028



E. S. Saibel’
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

Yegor S. Saybel - Leading Specialist, Department of Methodological Support of Comprehensive HTA.

10-5 Khokhlovskii pereulok, Moscow 109028



M. V. Avksent’eva
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution; Sechenov First Moscow State Medical University
Russian Federation

Maria V. Avxentyeva - MD, PhD, Advisor to the Director - General, CHQAC, MH RF; Leading Research Fellow at the Center of Finance in Health Care, FRI, MF RF, Professor at the High School of Health Administration, Sechenov FSMU.

10-5 Khokhlovskii pereulok, Moscow 109028; 3-2 Nastasyinsky pereulok, Moscow 127006; 8-2 Trubetskaya Str., Moscow 119048



M. V. Sura
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Russian Federation

Mariya V. Sura - MD, PhD, Head of the Scientific and Research Department, CHQAC, MH RF, Leading Researcher at the Center for Health Technology Assessment, Institute for Applied Economic Research, Russia Presidential Academy of National Economy and Public Administration of (RANEPA).

10-5 Khokhlovskii pereulok, Moscow 109028



D. V. Fedyaev
Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation; Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution; Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education
Russian Federation

Denis V. Fedyaev - Deputy Head of the Department for Methodological Support of Methods of Payment for Medical Aid, CHQAC, MH RF, Research Fellow at the Laboratory for HTA, IAER RAS, Research Associate at the Health Care Finance Research Center.

10-5 Khokhlovskii pereulok, Moscow 109028; 3-2 Nastasyinsky pereulok, Moscow 127006; 82 Vernadskogo prospect, Moscow 119571



References

1. World Health Organization. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy. 2000; 2003; 2000; 81 pp.

2. Shastitko A. et al. Consequences of weak competition: quantitative assessments and policy implications (Expert-analytical report of the RANEPA). Ekonomicheskaya politika (in Russ). 2012; 6: 5-53.

3. Kulikov A.Yu., Misikova B.B. Pharmacoeconomic evaluation of the use of the drug Revlimid (lenalidomide) for the treatment of patients with multiple myeloma. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya/FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology (in Russ). 2012; 5 (1): 13-19.

4. Kulikov A.Yu., Babii V.V. Validation of the prognostic pharmacoeconomic model for the introduction of the drug emtricitabine / rilpi-virin / tenofovir (“Evipler”) into the practice of highly active antiretroviral therapy for patients with HIV infection in the Russian Federation. Pharmacoeconomics: theory and practice. Farmakoekonomika: teoriya ipraktika (in Russ). 2015; 3 (2): 82-87.

5. Yagudina R.I., Tishchenko D.G. Validation of the prognostic pharmacoeconomic model for incorporating the drug Ibrutinib into the practice of treating chronic lymphocytic leukemia in the territory of the Russian Federation. Pharmacoeconomics: theory and practice. Farmakoekonomika: teoriyaipraktika (in Russ). 2015: 3 (3): 37-40.

6. Mulcahy A.W., Hlavka J.P., Case S.R. BiosimilarCostSavings in the United States: Initial Experience and Future Potential. Santa Monica, CA: RAND Corporation, 2018.

7. Bennett C.L. et al. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. The Lancet Oncology. 2017; l (18): 2223.8.

8. Avxentyeva M.V. et al. New Approaches to the Development of Diagnostic Related Groups for Cancer Pharmacotherapy in Russian Federation. Medical Technologies. Assessment and Choice. 2018; 32 (2): 8-23.

9. State Register of Medicines [Electronic resource] URL: http://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 23.03.2019.

10. SiteIAS “Purchases” [Electronic resource] URL: http://gzakupki.com. Accessed: 23.03.2019.


For citation:


Gorkavenko F.V., Nikitina A.V., Saibel’ E.S., Avksent’eva M.V., Sura M.V., Fedyaev D.V. Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(2):115-124. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.2.115-124

Views: 110


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)